Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Solution Conformations Shed Light on PROTAC Cell Permeability
Yoseph Atilaw, Vasanthanathan Poongavanam, Caroline Svensson Nilsson, et al.
ACS Medicinal Chemistry Letters (2020) Vol. 12, Iss. 1, pp. 107-114
Open Access | Times Cited: 135

Showing 1-25 of 135 citing articles:

PROTAC targeted protein degraders: the past is prologue
Miklós Békés, David R. Langley, Craig M. Crews
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 3, pp. 181-200
Open Access | Times Cited: 1651
PROTACs: past, present and future
Ke Li, Craig M. Crews
Chemical Society Reviews (2022) Vol. 51, Iss. 12, pp. 5214-5236
Open Access | Times Cited: 376
Recent Developments in PROTAC‐Mediated Protein Degradation: From Bench to Clinic
Zhenyi Hu, Craig M. Crews
ChemBioChem (2021) Vol. 23, Iss. 2
Open Access | Times Cited: 148
A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo
Christiane Kofink, Nicole Trainor, Barbara Mair, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 131
From Conception to Development: Investigating PROTACs Features for Improved Cell Permeability and Successful Protein Degradation
Carlotta Cecchini, Sara Pannilunghi, Sébastien Tardy, et al.
Frontiers in Chemistry (2021) Vol. 9
Open Access | Times Cited: 119
Direct-to-Biology Accelerates PROTAC Synthesis and the Evaluation of Linker Effects on Permeability and Degradation
Charles E. Hendrick, Jeff R. Jorgensen, Charu Chaudhry, et al.
ACS Medicinal Chemistry Letters (2022) Vol. 13, Iss. 7, pp. 1182-1190
Open Access | Times Cited: 88
Degrader-antibody conjugates
Peter S. Dragovich
Chemical Society Reviews (2022) Vol. 51, Iss. 10, pp. 3886-3897
Closed Access | Times Cited: 76
Linker-Dependent Folding Rationalizes PROTAC Cell Permeability
Vasanthanathan Poongavanam, Yoseph Atilaw, Stephan Siegel, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 19, pp. 13029-13040
Open Access | Times Cited: 66
Discovery of Sulanemadlin (ALRN-6924), the First Cell-Permeating, Stabilized α-Helical Peptide in Clinical Development
Vincent Guerlavais, Tomi K. Sawyer, Luis A. Carvajal, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 14, pp. 9401-9417
Closed Access | Times Cited: 55
Trends in Molecular Properties, Bioavailability, and Permeability across the Bayer Compound Collection
Daniel H. O’Donovan, Claudia De Fusco, Lara Kuhnke, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 4, pp. 2347-2360
Closed Access | Times Cited: 49
Delivering on the promise of protein degraders
Matthew N. O’Brien, Suman Luthra, Matthew F. Brown, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 5, pp. 410-427
Closed Access | Times Cited: 48
Advancing Strategies for Proteolysis-Targeting Chimera Design
Minglei Li, Ying Zhi, Bo Liu, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 4, pp. 2308-2329
Closed Access | Times Cited: 42
Beyond Rule of Five and PROTACs in Modern Drug Discovery: Polarity Reducers, Chameleonicity, and the Evolving Physicochemical Landscape
Edward Price, Manuel Weinheimer, Alexey Rivkin, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 7, pp. 5683-5698
Closed Access | Times Cited: 16
Degraders upgraded: the rise of PROTACs in hematological malignancies
Joshua Casan, John F. Seymour
Blood (2024) Vol. 143, Iss. 13, pp. 1218-1230
Closed Access | Times Cited: 13
Discovery of CBPD-268 as an Exceptionally Potent and Orally Efficacious CBP/p300 PROTAC Degrader Capable of Achieving Tumor Regression
Zhixiang Chen, Mi Wang, Dimin Wu, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 7, pp. 5275-5304
Closed Access | Times Cited: 13
Exploring the chemical space of orally bioavailable PROTACs
Giulia Apprato, Vasanthanathan Poongavanam, Diego García Jiménez, et al.
Drug Discovery Today (2024) Vol. 29, Iss. 4, pp. 103917-103917
Open Access | Times Cited: 12
Amide-to-Ester Substitution as a Strategy for Optimizing PROTAC Permeability and Cellular Activity
Victoria G. Klein, Adam G. Bond, Conner Craigon, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 24, pp. 18082-18101
Open Access | Times Cited: 88
A bibliometric analysis of PROTAC from 2001 to 2021
Deping Li, Dongmin Yu, Yan Li, et al.
European Journal of Medicinal Chemistry (2022) Vol. 244, pp. 114838-114838
Closed Access | Times Cited: 59
PROTAC technology: A new drug design for chemical biology with many challenges in drug discovery
Nicolas Guedeney, Marie Cornu, Florian Schwalen, et al.
Drug Discovery Today (2022) Vol. 28, Iss. 1, pp. 103395-103395
Open Access | Times Cited: 58
Impact of PROTAC Linker Plasticity on the Solution Conformations and Dissociation of the Ternary Complex
Dhanushka Weerakoon, Rodrigo J. Carbajo, Leonardo De Maria, et al.
Journal of Chemical Information and Modeling (2022) Vol. 62, Iss. 2, pp. 340-349
Closed Access | Times Cited: 53
Designing Soluble PROTACs: Strategies and Preliminary Guidelines
Diego García Jiménez, Matteo Rossi Sebastiano, Maura Vallaro, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 19, pp. 12639-12649
Open Access | Times Cited: 52
PROTAC degraders as chemical probes for studying target biology and target validation
Václav Němec, Martin P. Schwalm, Susanne Müller, et al.
Chemical Society Reviews (2022) Vol. 51, Iss. 18, pp. 7971-7993
Closed Access | Times Cited: 48
Industry Perspective on the Pharmacokinetic and Absorption, Distribution, Metabolism, and Excretion Characterization of Heterobifunctional Protein Degraders
Laurie P. Volak, Heide Marika Duevel, Sara C. Humphreys, et al.
Drug Metabolism and Disposition (2023) Vol. 51, Iss. 7, pp. 792-803
Closed Access | Times Cited: 27
A beginner’s guide to current synthetic linker strategies towards VHL-recruiting PROTACs
Nikol A. Zografou-Barredo, Alex J. Hallatt, J. S. JUN. RICCI, et al.
Bioorganic & Medicinal Chemistry (2023) Vol. 88-89, pp. 117334-117334
Open Access | Times Cited: 27
Current advances of small molecule E3 ligands for proteolysis-targeting chimeras design
Dazhao Mi, Yuzhan Li, Haijun Gu, et al.
European Journal of Medicinal Chemistry (2023) Vol. 256, pp. 115444-115444
Closed Access | Times Cited: 25
Page 1 - Next Page

Scroll to top